Solid Biosciences (SLDB) said it will provide a corporate update at the J.P. Morgan Healthcare Conference later Wednesday outlining its expanded clinical-stage pipeline and 2025 objectives.
Among the highlights from the presentation include its SGT-003 for Duchenne muscular dystrophy and SGT-212 for Friedreich's ataxia, Solid said. It said SGT-003 continued to be well tolerated in the first four patients dosed in an ongoing trial.
The company said it has resources to fund its key strategic priorities into 2026.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。